Drugs & Therapy Perspectives

, Volume 18, Issue 5, pp 16–20 | Cite as

Tumour necrosis factor-α blockers: increasing the options for managing rheumatoid arthritis

Disease Management


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Keating GM, Jarvis B. Management of rheumatoid arthritis: defining the role of etanercept. Dis Manage Health Outcomes 2002; 10(1): 17–39CrossRefGoogle Scholar
  2. 2.
    Jarvis B, Faulds D. Etanercept. A review of its use in rheumatoid arthritis. Drugs 1999 Jun; 57(6): 945–66PubMedCrossRefGoogle Scholar
  3. 3.
    Wolfe F, Cush JJ, O’Dell JR, et al. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol 2001 Jun; 28: 1423–30PubMedGoogle Scholar
  4. 4.
    Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000 Jun; 59(6): 1341–59PubMedCrossRefGoogle Scholar
  5. 5.
    Richard-Miceli C, Dougados M. Tumour necrosis factorα blockers in rheumatoid arthritis. BioDrugs 2001; 15(4): 251–59PubMedCrossRefGoogle Scholar
  6. 6.
    British National Formulary. No 42. London: The Pharmaceutical Press, 2001 Sep: 485Google Scholar
  7. 7.
    Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor amonoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932–9PubMedCrossRefGoogle Scholar
  8. 8.
    Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93PubMedCrossRefGoogle Scholar
  9. 9.
    Spencer-Green G, Genovese M, Martin RW, et al. Etanercept versus methotrexate in early rheumatoid arthritis (ERA trial): two-year follow-up [abstract]. J Rheumatol 2001 Jul; 28 Suppl. 63: 106Google Scholar
  10. 10.
    Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized controlled study. Arch Intern Med 1999; 130: 478–86Google Scholar
  11. 11.
    Weinblatt ME, Kremer JM, Bankhurst, AD, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9PubMedCrossRefGoogle Scholar
  12. 12.
    Jones M, Symmons D, Finn J, et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996; 35: 738–45PubMedCrossRefGoogle Scholar
  13. 13.
    Infliximab (Remicade®): prescribing information. Malvern (PA): Centocor, 1999.Google Scholar
  14. 14.
    Smolen JS, Steiner G, Breedveld FC, et al. Anti-TNFα therapy and drug-induced lupus-like syndrome [abstract no. 906]. Ann Rheum Dis 1999 Jun 6; EULAR Suppl.: 217Google Scholar
  15. 15.
    Emery P, Reginster JY, Appelboom T, et al. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 699–702CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations